Evaluation of Carvedilol for the Treatment of Portal Hypertension

Pharmacotherapy - Tập 24 Số 1 - Trang 94-104 - 2004
Brian A. Hemstreet1
1Department of Clinical Pharmacy, University of Colorado School of Pharmacy, Denver, Colorado.

Tóm tắt

Development of bleeding gastroesophageal varices is a serious consequence of portal hypertension secondary to cirrhosis. Nonselective β‐blockers have been used to reduce portal pressures and prevent primary and secondary bleeding episodes. However, up to two thirds of patients may not respond appropriately to these agents. Nonselective β‐blockers combined with vasodilatory drugs result in enhanced lowering of portal pressures by targeting several mechanisms involved in this process. Unfortunately, this practice is associated with increased adverse effects, such as hypotension, and minimal reductions in mortality. Carvedilol possesses both nonselective β‐antagonist and α1‐receptor antagonist activity. Given its combined mechanism of action, carvedilol presents a potential option for lowering portal pressures. Its effects on lowering portal pressures and its role in therapy are undefined. Using MEDLINE (1966–2003) and International Pharmaceutical Abstracts (1970–2003), the English‐language literature was searched to identify human studies assessing carvedilol's effects on lowering portal pressure. In general, carvedilol therapy was associated with mean reductions of 16–43% in portal pressure, assessed by the hepatic venous pressure gradient (HVPG) after single and multiple doses. Studies comparing carvedilol with propranolol revealed equal or enhanced efficacy in lowering HVPG. Large percentages of patients had significant HVPG reductions to levels that prevent variceal bleeding. Carvedilol also was associated with substantial symptomatic hypotension, especially in patients with ascites or Child‐Pugh class B or C cirrhosis. Efficacy and adverse effects generally seem to be dose related. Carvedilol appears to be a potentially viable option for treating portal hypertension. Further multiple‐dose trials comparing carvedilol with standard therapy are needed to assess the agent's long‐term safety and effectiveness in preventing variceal bleeding.

Từ khóa


Tài liệu tham khảo

10.1136/bmj.322.7282.348

10.1056/NEJMra003007

10.1053/gast.2001.22580

10.1055/s-2007-1007133

10.1016/S0140-6736(95)91740-3

10.1055/s-2001-11666

10.1056/NEJM199105303242202

10.7326/0003-4819-117-1-59

10.1002/hep.510250112

10.1016/S0016-5085(98)70372-5

10.1053/jhep.2001.27545

10.1136/bmj.291.6495.561

10.3109/00365529108998595

10.1056/NEJM199812103392407

10.2165/00003495-198800366-00026

10.1097/00005344-199219001-00028

10.1002/chir.530050102

10.1016/S0168-8278(96)80296-0

Sekiyama T., 1997, Effects of the α‐/β‐blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension, Arzneimittelforschung, 47, 353

10.1016/S0168-8278(99)80108-1

10.1002/hep.510300124

10.1046/j.1365-2036.2002.01190.x

10.1046/j.1440-1746.2002.02674.x

10.1111/j.1572-0241.2000.02266.x

10.1002/hep.1840360612

LaGow B., 2003, 2003 drug topics red book

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 24 Số 1

94-104

Thông tin tác giả